Cerevast Therapeutics

Cerevast Therapeutics, Inc. is a medical technology company with primary emphasis in the field of SonoLysis for the treatment acute ischemic stroke and other vascular disorders. This non-invasive treatment is administered with Cerevast’s proprietary ultrasonic headframe called the ClotBust-ERTM, an operator independent device that can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.

Cerevast was formed in September of 2009 following the acquisition of substantially all of the assets of ImaRx Therapeutics, Inc. – a publicly traded company focused on the development of microsphere contrast agents and therapeutics. Through this acquisition, Cerevast gained title to the dominant intellectual property estate and an extensive data package of pre-clinical and clinical studies.

Cerevast has assembled a management team with extensive technical, scientific, commercial and regulatory expertise. The company has also assembled a Scientific Advisory Board comprised of globally recognized clinicians, all of whom are leading experts in the field of SonoLysis, ultrasound development and stroke treatment.

The company’s headquarters are located in Redmond, Washington.

Redmond, US
7 (est)-53%

Cerevast Therapeutics Locations

Redmond, US

Cerevast Therapeutics Metrics

Cerevast Therapeutics Summary

Founding Date


Total Funding

$45.4 M

Latest funding size

$11.4 M

Time since last funding

over 1 year


Cerevast Therapeutics News